Our Mission:

To Provide Societal Benefit by Cost Effectively Saving Lives and Reducing Morbidity Worldwide

XCellCure’s products under development have been carefully selected to provide rapid information used to elucidate the risk of impending heart attack. Our novel multimarker proteomics assay creates a “Signature of Disease” allowing physicians to quickly intervene with proven medical therapies that will save lives and reduce morbidity associated with aging. 

Meet Our First Product: The AMiAware

The XCellCure AMiAware is Designed to Provide a Clear and Accurate Picture of Cardiac Risk to Reduce the Incidence of Heart Disease and Death due to Heart Attack

Utilizing 13 novel cardiovascular biomarkers acting together as risk indicators, the AMiAware identifies patients at risk for fatal events after experiencing symptoms of a Heart Attack. This device creates a “Signature of Disease” specific to each patient. Pushing acute cardiovascular care into the modern day realm of personalized medicine, this “signature” guides care providers in administering prompt and effective therapeutic interventions suited best to each individual.

Revolutionizing care for patients with acute coronary syndromes, the XCellCure planned line of products will allow physicians to noninvasively diagnose and prognosticate victims of Heart Attack with accuracy, ease, and speed previously unknown in the clinic. Want to learn more? Contact us!

Sobering U.S. Heart Attack Statistics

8 million patients present to the emergency room complaining of chest pain and indeterminate symptoms of a heart attack each year.

Approximately 610,000 Americans die of heart disease in the United States every year. That is 1 in every 4 deaths. Heart disease is the leading cause of death for both men and women in the United States.

735,000 Americans per year will experience an Acute Myocardial Infarction, also known as a Heart Attack. For 1/3 of these patients, this will be both is their first and only heart attack, resulting in fatality.

Of the patients who experience heart attack each year, 210,000 will have a recurrent attack. This shocking number illuminates a pressing need for better diagnostics, monitoring and therapeutics in the clinical setting.

Each patient that steps through the emergency room doors experiencing symptoms of heart attack will stay in the hospital for an average of 4.6 days, costing traditional health insurers over $38,000 for the first 90 days following the event alone. 

Over the next 20 years the costs of Cardiovascular disease in the United States is expected by both the CDC and American Heart Association to increase to over $800 billion.